Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
Jason P. Holland(University of Zurich), Jason S. Lewis(Memorial Sloan Kettering Cancer Center)
Cited by 129
Related Papers
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306
A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels–Alder Click Chemistry
|Journal of Nuclear Medicine|2013|301
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
|Science Signaling|2014|166
1-<sup>11</sup>C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer
|Journal of Nuclear Medicine|2008|154
Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with <sup>18</sup>F-FDG and <sup>89</sup>Zr-Trastuzumab PET
|Journal of Nuclear Medicine|2013|93